6-methyl-2-(bromoacetyl)naphthalene | 62244-81-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-methyl-2-(bromoacetyl)naphthalene
• 英文别名: ω-Brom-6-methyl-2-acetonaphthon；6-Methyl-ω-Brom-2-acetonaphton；6-Methyl-2-(bromacetyl)-naphthalin；2-Bromo-1-(6-methylnaphthalen-2-yl)ethan-1-one；2-bromo-1-(6-methylnaphthalen-2-yl)ethanone
• CAS: 62244-81-9
• 化学式: C₁₃H₁₁BrO
• 分子量: 263.134
• InChiKey: UYZKBDOVBQHHHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-萘乙酮 、 6-methyl-2-(bromoacetyl)naphthalene 在 二乙胺 、 zinc(II) chloride 、 叔丁醇 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Acylguanidine inhibitors of β-secretase: Optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets

  摘要：

  Proteolytic cleavage of amyloid precursor protein by beta-secretase (BACE-1) and gamma-secretase leads to formation of beta-amyloid (A beta) a key component of amyloid plaques, which are considered the hallmark of Alzheimer's disease. Small molecule inhibitors of BACE-1 may reduce levels of A beta and thus have therapeutic potential for treating Alzheimer's disease. We recently reported the identification of a novel small molecule BACE-1 inhibitor N-[2-(2,5-diphenyl-pyrrol-1-yl)-acetyl]guanidine (3.a.1). We report here the initial hit-to-lead optimization of this hit and the SAR around the aryl groups occupying the S-1 and S-2' pockets leading to submicromolar BACE-1 inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.010
• 作为产物：
  描述：

  1-(6-甲基-2-萘基)乙酮 在 copper(ll) bromide 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 生成 6-methyl-2-(bromoacetyl)naphthalene
  参考文献：
  名称：

  1-（萘基烷基）-1H-咪唑衍生物，一类新的抗惊厥药。

  摘要：

  对于在亚烷基桥中含有各种官能团的大量1-（萘基烷基）-1H-咪唑已显示出有效的抗惊厥活性。通常，桥中小的氧功能的存在在抗惊厥和抑郁活性之间赋予较高的治疗指数。讨论了1-（2-萘甲酰基甲基）咪唑盐酸盐（5）的临床期望，该盐正在开发用于人体测试。

  DOI：

  10.1021/jm00133a015

文献信息

• [EN] 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE UTILISÉS EN TANT QU'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2020022794A1

  公开（公告）日：2020-01-30

  The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, a pharmaceutical use thereof, and a method for preparing the same. According to the present invention, the novel compounds, optical isomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; internal secretion; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, and chromosomal aberration.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其光学异构体或其药学上可接受的盐，其药用用途以及其制备方法。根据本发明，这些新化合物，其光学异构体或其药学上可接受的盐具有组蛋白去乙酰化酶6（HDAC6）抑制活性，并且在预防或治疗与HDAC6相关的疾病方面具有有效性，包括传染病；肿瘤；内分泌；营养和代谢疾病；精神和行为障碍；神经系统疾病；眼部和眼附器疾病；循环系统疾病；呼吸系统疾病；消化系统疾病；皮肤和皮下组织疾病；肌肉骨骼系统和结缔组织疾病；以及畸形或变形和染色体异常。
• VIOLET LASER EXCITABLE DYES AND THEIR METHOD OF USE
  申请人：LIFE TECHNOLOGIES CORPORATION

  公开号：US20160355682A1

  公开（公告）日：2016-12-08

  The present invention provides dye compounds optimally excited at about 400 nm and have a Stokes shift of at least about 80 nm. These dyes find use in detection of analyte in a sample and the preparation of dye-conjugates.

  本发明提供了染料化合物，最佳激发波长约为400纳米，并且具有至少约80纳米的斯托克斯位移。这些染料在样品中检测分析物和制备染料共轭物中得到应用。
• GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE
  申请人：Greenlee William J.

  公开号：US20110065634A1

  公开（公告）日：2011-03-17

  The present invention relates to compounds of general formula (I), wherein ring A, ring B, R 1 , R 2 , R 3 , Z, and L 1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

  本发明涉及一般式（I）的化合物，其中环A、环B、R1、R2、R3、Z和L1彼此独立选择，并且如此定义，以及包含这些化合物的组合物，以及将这些化合物用作胰高血糖素受体拮抗剂和治疗或预防2型糖尿病及相关疾病的方法。
• 1-((Substituted-naphthyl)ethyl)-imidazole derivatives, pharmaceutical compositions containing them and methods of making them
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0016587A1

  公开（公告）日：1980-10-01

  Compounds of the formula wherein m is the integer 1, 2 or 3; R is independently selected from the group C1 to C6 alkyl, C1 to C6 alkoxy, halo, trifluoromethyl and hydroxy when m is the integer 1, or 3 and methylenedioxy when m is the integer 2; Z is hydroxymethylene, esterified hydroxymethylene, alkoxymethylene, alkylthiomethylene, carbonyl, or ketal-, thioketal- or hemithioketal-protected carbonyl, and the pharmaceutically acceptable acid addition salts thereof, are useful as anticonvulsants, anti-secretory agents and spermatocides.

  式中的化合物 其中 m 为整数 1、2 或 3；当 m 为整数 1 或 3 时，R 独立选自 C1 至 C6 烷基、C1 至 C6 烷氧基、卤代、三氟甲基和羟基，当 m 为整数 2 时，R 独立选自亚甲基二氧基；Z 是羟亚甲基、酯化羟亚甲基、烷氧基亚甲基、烷硫亚甲基、羰基或酮基、硫酮基或半硫酮基保护的羰基，及其药学上可接受的酸加成盐可用作抗惊厥剂、抗分泌剂和杀精剂。
• Rajasekaran, K.; Baskaran, T.; Gnanasekaran, C., Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical and Analytical, 1984, vol. 23, # 12, p. 1008 - 1010
  作者：Rajasekaran, K.、Baskaran, T.、Gnanasekaran, C.

  DOI：——

  日期：——